NK520

DRUG2 trials

Sponsors

Base Therapeutics (Shanghai) Co., Ltd.

Conditions

Relapsed/Refractory Acute Myeloid Leukemia

Early Phase 1

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

RecruitingNCT06541405

Base Therapeutics (Shanghai) Co., Ltd.Relapsed/Refractory Acute Myeloid Leukemia

Start: 2024-07-01End: 2025-06-01Target: 9Updated: 2024-08-07

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

RecruitingNCT06541444

Base Therapeutics (Shanghai) Co., Ltd.Relapsed/Refractory Acute Myeloid Leukemia

Start: 2024-07-01End: 2026-06-01Target: 9Updated: 2024-08-07